[Changes in blood rheological properties in patients with hypertension].
OBJECTIVE
To study hemorheology in patients with essential hypertension (EH), to improve EH treatment in terms of blood rheology.


METHODS
Blood rheology, microcirculation, lipid plasm spectrum, central hemodynamics were studied in 90 patients with mild and 83 patients with moderate or severe EH as well as 30 healthy controls before and after treatment (hypotensive drugs, essential phospholipids, intravenous laser blood radiation, plasmapheresis).


RESULTS
Hemorrheological disorders (subnormal deformability of the red cells and elastoviscosity of their membranes, disk-spherical transformation and hyperaggregation of blood cells, high dynamic viscosity) correlated with the disease severity, arterial pressure and total peripheral vascular resistance. Long-term (1-1.5 years) hypotensive therapy, especially with combination of beta-blockers with diuretics, has a negative effect on blood rheology. Optimisation of EH treatment in terms of blood rheology consists in using essential phospholipids in stable hypertension, intravenous laser radiation in complicated hypertension, plasmapheresis in drug-resistant hypertension. Such an approach not only significantly improves hemorheology but also provides good clinical and hypotensive effects in 75-80% patients.


CONCLUSIONS
Blood viscodynamics should be taken into consideration in individual treatment of hypertensive patients.
Shabanov
V A
VA
Terekhina
E V
EV
Kostrov
V A
VA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001769:Blood / Q000528:radiation effects; D001809:Blood Viscosity; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004232:Diuretics; D004359:Drug Therapy, Combination; D005260:Female; D018056:Hemorheology; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000097:blood* / Q000628:therapy; D007834:Lasers; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D010743:Phospholipids / Q000627:therapeutic use; D010956:Plasmapheresis; D011433:Propranolol / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D004232:Diuretics; D010743:Phospholipids; D049993:Sodium Chloride Symporter Inhibitors; D006852:Hydrochlorothiazide; D011433:Propranolol; D009543:Nifedipine
Izmeneniia reologicheskikh svoĭstv krovi u bol'nykh gipertonicheskoĭ bolezn'iu.